Micafungin – Overview of Safety in Pediatric Patients

Background and aims: Children at risk of invasive fungal infections are often fragile hosts with multiple underlying conditions. Since drug safety is critical in such patients, we evaluated the safety of micafungin, a novel antifungal agent, by pooling pediatric safety data from clinical trials. Methods: Adverse event (AE) data were pooled from clinical trials conducted in Europe, the Americas and Asia. Results: 296 patients received at least one dose of micafungin. The mean±SD age was 6.5±5.1 years; 66 patients were